Urosource: Headline News

Novel investigational androgen drug shows higher survival rates in castration-resistant PCa

Edited by: JV

Friday, 3 February 2012- An investigational androgen receptor antagonist substantially boosts survival in castration-resistant prostate cancer, according to phase III trial results.

The oral agent, called MDV3100, improved overall survival by 37% for a nearly five month advantage compared with...

Interactive

Experimental antibody agent likely to improve survival outcomes for kidney transplant patients

Thursday, 2 February 2012- New research published online in the FASEB Journal details a new antibody, called "OPN-305" that may significantly improve survival outcomes for those receiving donated kidneys and other organs.

OPN-305 works by preventing inflammation triggered by oxygen...

Edited by: JV

Constipation, not the bladder, may cause bedwetting in children, says US research

Wednesday, 1 February 2012- Bedwetting isn't always due to problems with the bladder, according to new research by Wake Forest Baptist Medical Center in the US. Constipation is often the culprit; and if it isn't diagnosed, children and their parents must endure an unnecessarily long, costly and...

Edited by: JV

More key articles

Stopping immunosuppressive prednisone soon after kidney transplant found to be safe

Tuesday, 31 January 2012- Rapid discontinuation of the immunosuppressive steroid prednisone after a kidney transplant can help prevent serious side effects, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Also, doing so does...

Clinical nodal staging scores for bladder cancer

Monday, 30 January 2012- Radical cystectomy (RC) with pelvic lymph node dissection (LND) is the standard of care for refractory non-muscle-invasive and muscle-invasive bladder cancer. Although consensus exists on the need for LND, its extent is still debated.

S. Shariat and colleagues conducted a...

More headline news

FDA okays axitinib for advanced kidney cancer

Tuesday, 31 January 2012- The US Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of cancer.

Renal cell carcinoma is a type of kidney cancer that starts in the...

Preoperative MRI lowers risk of nerve damage in prostate cancer surgeries, says US study

Monday, 30 January 2012- Preoperative MRI helps surgeons make more informed decisions about nerve-sparing procedures in men with prostate cancer, according to a new study published online in the journal Radiology.

Excluding skin cancer, prostate cancer is the most common cancer diagnosed in...

More conference reports

Kidney cancer: every minute counts

Wednesday, 16 November 2011- The 3rd European Multidisciplinary Meeting on Urological Cancers (EMUC) raised a vast array of controversial issues in onco-urology and offered essential updates, providing common ground for building bridges across disciplines.

Organised by the European Association of...

EMUC debates stress importance of professional expertise in era of technological development

Tuesday, 15 November 2011- During the 3rd European Multidisciplinary Meeting on Urological Cancers in Barcelona the present and future of uro-oncological care was discussed in a number of excellent, thought-provoking debates. The latest issues and advances in the diagnosis and treatment of bladder,...

More upcoming

Vienna, Austria: 26th Annual EAU Congress tackles controversial issues in urology

Wednesday, 9 March 2011- Some of the most pressing issues in urology will be addressed next week during the 26th Annual EAU Congress in Vienna, Austria, from March 18 to 22. Four plenary sessions, which will open each of the congress days, will examine issues in uro-oncology, andrology, paediatric...

7th ESOU Meeting in Vienna to tackle emerging treatment options

Friday, 8 January 2010- Emerging treatment options that impact on the diagnosis of uro-genital cancers will be examined at the annual meeting of the EAU Section of Oncological Urology (ESOU) to be held in Vienna, Austria from January 15 to 17, 2010.

Prof. Bob Djavan, chairman of the 7th ESOU...